Vaccination with CD20 peptides induces a biologically active, specific immune response in mice

Blood

Volumn 99, Issue 10, 2002, Pages 3748-3755

  Roberts, Wendy K ^a,b   Livingston, Philip O ^a,b   Agus, David B ^a,b   Pinilla Ibarz, Javier ^a,b   Zelenetz, Andrew ^a,b   Scheinberg, David A ^a,b  

^a Weill Cornell Graduate School of Biomedical Sciences   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; VACCINATION;

EID: 0037092953     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.10.3748     Document Type: Article

References (35)

1. Characterization of a human B lymphocyte-specific antigen
2. Expression of cell surface markers after human B lymphocyte activation
3. Characterization of a human B cell-specific antigen (B2) distinct from B1
4. CD20: A regulator of cell-cycle progression of B lymphocytes
5. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2
6. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment
7. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes
8. Heterogeneity in the B1 (CD20) cell surface molecule expressed by human B-lymphocytes
9. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY
10. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines
11. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
12. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
13. Preclinical and phase I and II trials of rituximab
14. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors
15. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
16. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
17. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
18. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein
19. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice
20. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21
21. Developing recombinant and synthetic vaccines for the treatment of melanoma
22. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies
23. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: Comparison of different vaccine formulations
24. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines
25. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: Purified GM2 is superior to whole cells
26. GD3 vaccines for melanoma: Superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines
27. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice
28. Use of rituximab, the new FDA-approved antibody
29. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21
30. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma
31. Mice carrying a CD20 gene disruption
32. The central role of CD4(+) T cells in the antitumor immune response
33. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
34. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulat ing factor stimulates potent, specific, and longlasting anti-tumor immunity
35. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1 +,2- T cells, Tumor eradication does not require participation of cytotoxic T cells